Product Description
Avistone Biotechnology is developing PLB-1004, an oral EGFR inhibitor being studied in patients with non-small cell lung cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05347628?term=PLB-1004&draw=2&rank=1)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Avistone Biotechnology
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 12
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06281964 |
PLB1004-III-01 | P3 |
Enrolling by invitation |
Non-Small-Cell Lung Cancer |
2026-01-30 |
13% |
2025-06-14 |
Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20201030 |
CTR20201030 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-07-31 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20241361 |
CTR20241361 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-05-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20233128 |
CTR20233128 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2023-12-27 |
2025-04-29 |
||
NCT07063329 |
PLB1004 +Chemo-NSCLC-Ib/II-01 | P2 |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2028-03-08 |
2% |
2025-07-15 |
Primary Endpoints|Treatments |
NCT06343064 |
KYLIN-1 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2026-12-31 |
12% |
2025-05-21 |
Primary Endpoints |
NCT06574347 |
PLB1001/PLB1004-NSCLC-II-02 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2026-10-31 |
12% |
2024-08-28 |
|
CTR20231534 |
CTR20231534 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2025-03-10 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06015503 |
KANNON | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2025-03-06 |
2% |
2025-04-04 |
|
CTR20241781 |
CTR20241781 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
NCT06046495 |
PLB1004-I-US01 | P1 |
Recruiting |
Non-Small-Cell Lung Cancer |
2028-02-09 |
12% |
2024-07-24 |
|
NCT06970782 |
PLB1001/PLB1004-NSCLC-III-01 | P3 |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2027-12-31 |
58% |
2025-05-15 |
Primary Endpoints|Treatments |